Iovance Biotherapeutics, Inc. announced promising five-year follow-up results from the Phase 2 C-144-01 clinical trial of their T cell therapy Amtagvi® (lifileucel) for advanced melanoma. Published in ...
Iovance Biotherapeutics stock more than doubled in February after the Food and Drug Administration approved Amtagvi, its first drug. Amtagvi is a complicated cellular therapy made of ...
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company ...
SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...
Amtagvi shows a 48.8% ORR in advanced melanoma, with higher efficacy in less heavily treated patients. FDA granted accelerated approval for Amtagvi in 2024 for unresectable or metastatic melanoma ...
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...
I last covered Iovance Biotherapeutics (IOVA) in October, suggesting that while Q3 earnings may disappoint, ultimately, a long-term bull thesis remains in play. That has proven to be the case so far, ...
Hosted on MSN
Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption
The company reiterated full year 2025 revenue guidance of $250 million to $300 million, inclusive of Amtagvi and Proleukin sales. Management expects ongoing reductions in expenses and improvements in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without actionable mutations. The median duration of response was not reached after 25.4 ...
Iovance's leading candidate should make regulatory progress in the next five years. The biotech company's pipeline could also make exciting breakthroughs. Its stock could have substantial upside, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results